Related Experiment Video
Updated: Aug 19, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Natural history of hepatitis B
P Marcellin1, C Castelnau, M Martinot-Peignoux
1INSERM U-481, Beaujon Hospital, Clichy, France. patrick.marcellin@bjn.ap-hop-paris.fr
Insights
Chronic hepatitis B infection can progress to severe liver disease, including cirrhosis and liver cancer. HBeAg-negative hepatitis B, a late-stage infection, is increasing and associated with poorer outcomes.
Area of Science:
- Hepatology
- Virology
- Gastroenterology
Background:
- Chronic hepatitis B virus (HBV) infection presents diverse clinical courses.
- Infection can range from inactive carrier state to progressive hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).
- HBeAg-positive and HBeAg-negative hepatitis B represent distinct phases with differing prognoses.
Purpose of the Study:
- To describe the natural history and clinical significance of chronic hepatitis B.
- To highlight the increasing prevalence and severity of HBeAg-negative chronic hepatitis B.
- To outline the progression, morbidity, and mortality associated with chronic HBV infection.
Main Methods:
- Review of longitudinal studies on chronic hepatitis B patients.
- Analysis of disease progression, including development of cirrhosis and hepatic decompensation.
- Examination of survival rates based on disease severity and cirrhosis status.
Main Results:
- HBeAg-negative chronic hepatitis B, caused by HBV variants, is increasing globally and represents the majority of cases in many regions.
- This late-phase infection is linked to more severe liver disease, low spontaneous remission rates, and poor response to antiviral therapy.
- The 5-year cumulative incidence of cirrhosis is 8-20%, hepatic decompensation is ~20%, and survival varies significantly with cirrhosis severity.
Conclusions:
- HBeAg-negative chronic hepatitis B is a significant and growing public health concern with a poorer prognosis.
- Progression to cirrhosis and HCC are the main drivers of morbidity and mortality in chronic HBV infection.
- Effective management and monitoring are crucial to improve outcomes for patients with chronic hepatitis B, particularly the HBeAg-negative form.
Abstract:
The natural course of hepatitis B virus (HBV) chronic infection is variable, ranging from an inactive HBsAg carrier state to a more or less progressive chronic hepatitis, potentially evolving to cirrhosis and hepatocellular carcinoma (HCC). Chronic hepatitis may present as typical HBeAg-positive chronic hepatitis B or HBeAg-negative chronic hepatitis B. HBeAg-positive chronic hepatitis is due to wild type HBV; it represents the early phase of chronic HBV infection. HBeAg-negative chronic hepatitis is due to a naturally occurring HBV variant with mutations in the precore or/and basic core promoter regions of the genome; it represents a late phase of chronic HBV infection. The latter form of the disease has been recognized as increasing in many countries within the last decade and it represents the majority of cases in many countries. HBeAg-negative chronic hepatitis B is generally associated with a more severe liver disease with a very low rate of spontaneous disease remission and a low sustained response rate to antiviral therapy. Longitudinal studies of patients with chronic hepatitis B indicate that, after diagnosis, the 5-year cumulative incidence of developing cirrhosis ranges from 8-20%. Morbidity and mortality in chronic hepatitis B are linked to evolution to cirrhosis or HCC. The 5-year cumulative incidence of hepatic decompensation is approximately 20%. The 5-year probability of survival is approximately 80-86% in patients with compensated cirrhosis. Patients with decompensated cirrhosis have a poor prognosis (14-35% probability of survival at 5 years). HBV-related end-stage liver disease or HCC are responsible for at least 500,000 deaths per year.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Cirrhosis I: Introduction
Yellow Fever
Viruses with RNA Genomes
Retroviruses

